PT  - JOURNAL ARTICLE
AU  - O Le Saux
AU  - AM Savoye
AU  - MA Mouret-Reynier
AU  - C Schiffler
AU  - O Derbel
AU  - T Isabelle
AU  - E Kalbacher
AU  - S Gouerant
AU  - A Martinez
AU  - C Cornila
AU  - M Martinez
AU  - L Bengrine Lefevre
AU  - F Priou
AU  - N Cloarec
AU  - L Venat-Bouvet
AU  - A Angelergues
AU  - D Berton
AU  - O Collard
AU  - E Coquan
AU  - I Ray-Coquard
TI  - 260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)
AID  - 10.1136/ijgc-2021-ESGO.369
DP  - 2021 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - A216--A217
VI  - 31
IP  - Suppl 3
4099  - http://ijgc.bmj.com/content/31/Suppl_3/A216.short
4100  - http://ijgc.bmj.com/content/31/Suppl_3/A216.full
SO  - Int J Gynecol Cancer2021 Oct 01; 31
AB  - Introduction/Background*In the randomized phase II NeoPembrOV study (NCT03275506), Pembrolizumab in combination with neoadjuvant chemotherapy (NACT) met its primary endpoint of complete debulking rate (CRR) for the treatment of patients with advanced up-front non-resectable high-grade serous ovarian cancer (HGSOC). However, the CRR in the control group was similar. Identification of potential predictive biomarkers is fundamental to better understand the place of Pembrolizumab in this setting.Methodology 91 Patients (pts) with HGSOC unable to received complete upfront debulking surgery were included and received Carboplatin (AUC5) Q3W + Paclitaxel (175mg/m2) Q3W +/- Pembrolizumab 200 mg Q3W IV before and after surgery. Pembrolizumab was given until 24 months maximum. After interval debulking surgery, optional bevacizumab was proposed. BRCA1/2 mutation status (BRCA) was assessed using standard algorithms. Immunohistochemical PD-L1 expression was evaluated on both tumour and immune cells (IC) using the Ventana SP263 assay. Associations of progression-free survival (PFS) with BRCA, and PD-L1 expression were evaluated.Result(s)* BRCA status was available for 81 pts (89%). 3 out of 30 pts (10%) in the control arm harboured a BRCA mutation (mBRCA) versus 13/61 in the experimental arm (21.3%). Median PFS (mPFS) in both arms in the BRCA wild-type (wtBRCA) subgroup were not different (mPFS 20.8 months [95% IC,15.0-25.7] vs 18.2 months [95%IC, 16.8.0-21.4] in control and experimental arms respectively). mPFS in the mBRCA subgroup were not reached in both arms. PD-L1 expression was available for 85/91 patients (93.4%). PD-L1 IC ≥5% was positive in 29/85 patients (34.1%) and correlated to mPFS in the whole population (18.2m in PDL1 IC<5% vs 23.4m PD-L1 IC ≥5% respectively, p=0.02). mPFS was similar HR: 1.39 [0.71-2.74] in patients with PD-L1 IC<5% (mPFS 19.3mo [14.9-25.7] vs mPFS 18.2mo [14.5-19.3] in control and experimental arms respectively). Pembrolizumab improved mPFS (HR: 0.56 [0.19-1.61]) for pts with PD-L1≥5% (mPFS 20.8 mo [9.5-NE] vs mPFS 23.4mo [18.0-NE] in control and experimental arms respectively).Conclusion*If no benefit in adding Pembrolizumab to CT +/- bevacizumab was found in wtBRCA subgroup, exploratory PFS analyses in the PD-L1 IC ≥5% subgroup showed a trend favouring Pembrolizumab in patients with advanced HGSOC.